300,000 Shares in Septerna, Inc. (NASDAQ:SEPN) Acquired by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. acquired a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 300,000 shares of the company's stock, valued at approximately $6,870,000. Adage Capital Partners GP L.L.C. owned about 0.68% of Septerna at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. TRV GP V LLC acquired a new position in shares of Septerna in the 4th quarter valued at $142,337,000. TRV GP VI LLC acquired a new position in Septerna in the fourth quarter valued at about $72,191,000. Avoro Capital Advisors LLC bought a new position in Septerna during the fourth quarter worth about $25,419,000. Vanguard Group Inc. acquired a new position in shares of Septerna during the 4th quarter worth about $22,557,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Septerna in the 4th quarter valued at about $11,877,000.

Septerna Stock Performance

SEPN stock traded up $0.18 during mid-day trading on Thursday, hitting $7.14. 210,635 shares of the company were exchanged, compared to its average volume of 422,148. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The business has a 50 day simple moving average of $6.06.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million. Analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insider Transactions at Septerna

In related news, Director Alan Ezekowitz acquired 7,491 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was bought at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the acquisition, the director now directly owns 24,911 shares of the company's stock, valued at approximately $158,184.85. The trade was a 43.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gil M. Labrucherie bought 10,500 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were bought at an average price of $5.51 per share, for a total transaction of $57,855.00. Following the acquisition, the chief financial officer now directly owns 10,500 shares of the company's stock, valued at $57,855. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired 74,346 shares of company stock valued at $439,670 in the last ninety days.

Analysts Set New Price Targets

Several research firms recently weighed in on SEPN. Wells Fargo & Company reduced their price objective on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday, March 28th. Cantor Fitzgerald restated an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.